Eli Lilly & Co. (LLY)

Price$1082.20

Value ScoreD

Growth ScoreB

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-10.02%

Price vs S&P 500 (4W)9.73%

VGM Score54.90

Market Capitalization$1.02T

P/E Ratio (Annual)49.19x

Indicated Dividend Yield (Annual)0.63%

All Metrics

P/CF (Annual)60.38x

Book Value / Share (Quarterly)$33.07

P/TBV (Annual)50.76x

Indicated Dividend (Annual)$6.92

Revenue Growth (3Y)31.69%

Cash Flow / Share (Quarterly)$10.99

Payout Ratio (TTM)22.10%

Price vs S&P 500 (YTD)-8.11%

Gross Margin (TTM)82.83%

Net Profit Margin (TTM)34.99%

EPS (TTM)$28.15

10-Day Avg Trading Volume3.26M

EPS Excl Extra (TTM)$28.15

Revenue Growth (5Y)21.58%

EPS (Annual)$22.95

Dividend / Share (Annual)$5.69

ROI (Annual)29.90%

Gross Margin (Annual)83.04%

Net Profit Margin (5Y Avg)22.43%

Cash / Share (Quarterly)$5.75

P/E Basic Excl Extra (TTM)40.16x

Revenue Growth QoQ (YoY)55.55%

EPS Growth (5Y)27.59%

P/E Normalized (Annual)49.19x

ROA (Last FY)18.35%

Revenue Growth TTM (YoY)47.44%

EBITD / Share (TTM)$37.37

ROE (5Y Avg)64.37%

Operating Margin (TTM)43.63%

Cash Flow / Share (Annual)$6.31

P/B Ratio32.54x

P/B Ratio (Quarterly)27.85x

Net Income / Employee (Annual)$412,800

EV / Revenue (TTM)14.58x

Net Interest Coverage (TTM)20.36x

ROA (TTM)22.73%

EPS Growth QoQ (YoY)169.45%

EV / EBITDA (TTM)31.38x

EPS Incl Extra (Annual)$22.95

Current Ratio (Annual)1.58x

Quick Ratio (Quarterly)0.73x

3-Month Avg Trading Volume3.23M

52-Week Price Return52.93%

EV / Free Cash Flow (Annual)176.61x

P/E Incl Extra (TTM)40.16x

Revenue / Employee (TTM)$1,445,000

Tangible BV / Share (Quarterly)$25.25

P/S Ratio (Annual)15.58x

Asset Turnover (Annual)0.58x

52-Week High$1149.10

Operating Margin (5Y Avg)26.78%

EPS Excl Extra (Annual)$22.95

CapEx CAGR (5Y)39.84%

Tangible BV CAGR (5Y)17.97%

26-Week Price Return5.91%

Quick Ratio (Annual)0.78x

13-Week Price Return8.12%

Total Debt / Equity (Annual)1.60x

Current Ratio (Quarterly)1.50x

Enterprise Value$1.05T

Revenue / Share Growth (5Y)21.93%

Asset Turnover (TTM)0.65x

Book Value / Share Growth (5Y)36.63%

Revenue / Employee (Annual)$1,303,600

Inventory Turnover (Annual)1.04x

Pretax Margin (Annual)39.48%

Cash / Share (Annual)$7.69

3-Month Return Std Dev37.35%

Gross Margin (5Y Avg)78.91%

Net Income / Employee (TTM)$505,500

EBITDA CAGR (5Y)30.83%

EBITDA Interim CAGR (5Y)44.31%

ROE (Last FY)77.78%

Net Interest Coverage (Annual)32.91x

EPS Basic Excl Extra (Annual)$22.95

P/FCF (TTM)97.92x

Receivables Turnover (TTM)4.74x

EV / Free Cash Flow (TTM)101.59x

Total Debt / Equity (Quarterly)1.39x

EPS Incl Extra (TTM)$28.15

Receivables Turnover (Annual)4.53x

ROI (TTM)37.71%

Dividend Growth Rate (5Y)15.17%

P/S Ratio (TTM)14.05x

Pretax Margin (5Y Avg)26.49%

Revenue / Share (Annual)$72.48

Tangible BV / Share (Annual)$21.18

Forward P/E27.51x

Free OCF CAGR (5Y)5.93%

Price vs S&P 500 (52W)24.72%

P/E Ratio (TTM)40.16x

EPS Growth TTM (YoY)128.83%

Year-to-Date Return2.82%

5-Day Price Return3.76%

EPS Normalized (Annual)$22.95

ROA (5Y Avg)12.81%

Net Profit Margin (Annual)31.67%

Month-to-Date Return18.23%

Cash Flow / Share (TTM)$7.21

EBITD / Share (Annual)$31.47

EPS Growth (3Y)49.25%

Operating Margin (Annual)40.35%

LT Debt / Equity (Annual)1.54x

P/CF (TTM)49.57x

ROI (5Y Avg)22.28%

P/E Excl Extra (TTM)40.16x

LT Debt / Equity (Quarterly)1.26x

EPS Basic Excl Extra (TTM)$28.15

P/TBV (Quarterly)36.48x

Payout Ratio (Annual)26.09%

P/B Ratio (Annual)38.29x

Dividend / Share (TTM)$5.91

Inventory Turnover (TTM)1.04x

Pretax Margin (TTM)43.08%

Book Value / Share (Annual)$28.09

Price vs S&P 500 (13W)-1.63%

Net Margin Growth (5Y)4.64%

Dividend Yield (TTM)0.55%

Beta0.52x

P/FCF (Annual)170.22x

Revenue / Share (TTM)$80.64

ROE (TTM)101.31%

52-Week Low$623.78

vGradeD

gGradeB

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 268.55est. 6.73

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.03

4.08

4.05

4.03

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64
VRTXVertex Pharmaceuticals Inc	D	B	C	$438.40

About

Eli Lilly is a pharmaceutical company with leading therapeutic portfolios in neuroscience, cardiometabolic disease, cancer, and immunology. The company's key franchises include blockbuster diabetes and obesity treatments (Mounjaro, Zepbound, Jardiance, Trulicity), foundational insulin products (Humalog, Humulin), the cancer therapy Verzenio, and immunology treatments (Taltz, Olumiant).